■分析口服二甲双胍对正常体重2型糖尿病患者肠道菌群特征和代谢物组成变化的影响。
■横断面研究中的T2DM患者给予二甲双胍12周。将未用药的T2DM患者作为对照组,观察二甲双胍方案治疗T2DM患者的各项指标。通过lluminaNovaSeq6000平台对研究对象的粪便肠道微生物群进行16SrDNA高通量基因测序。使用UPLC-MS/MS技术对研究对象的每个肠道微生物群代谢产物的14例进行靶向宏代谢组学。肠道菌群特征及其代谢产物之间的相关性,人体基本参数,糖脂代谢指标,采用spearman分析法对炎症因子进行分析。
■正常体重T2DM患者糖脂代谢指标和炎症因子水平高于健康人群(P<0.05),但是体重,BMI,腰围,正常体重T2DM患者的炎症因子浓度低于肥胖T2DM患者(P<0.05)。二甲双胍治疗改善T2DM患者糖脂代谢,但肥胖2型糖尿病患者糖脂代谢恢复更为明显.α-多样性指数差异无统计学意义(P>0.05),β-多样性差异有统计学意义(P<0.05)。与二甲双胍干预前相比,群落多样性和物种丰富度恢复,更接近健康人群。我们发现厌氧菌/木糖/核酮糖/木酮糖可能在二甲双胍治疗正常体重T2DM中通过改善血脂和减轻炎症发挥重要作用。二甲双胍可能通过Romboutsia在肥胖T2DM中发挥作用,中链脂肪酸(辛酸,癸酸,和十二烷酸)。
■正常体重T2DM患者肠道微生物菌群失调和代谢紊乱与糖脂代谢和全身炎症反应密切相关。二甲双胍治疗改善糖代谢水平,T2DM患者的全身炎症水平,更接近健康人口的状态。这种作用可能是通过影响肠道微生物群和微生物宿主共代谢产物来介导的,主要与厌氧菌和木糖/核糖/木酮糖有关。二甲双胍可能通过不同的途径在正常体重和肥胖T2DM患者中发挥作用。
UNASSIGNED: To analyze the effect of oral metformin on changes in gut microbiota characteristics and metabolite composition in normal weight type 2 diabetic patients.
UNASSIGNED: T2DM patients in the cross-sectional study were given metformin for 12 weeks. Patients with unmedicated T2DM were used as a control group to observe the metrics of T2DM patients treated with metformin regimen. 16S rDNA high-throughput gene sequencing of fecal gut microbiota of the study subjects was performed by llumina NovaSeq6000 platform. Targeted macro-
metabolomics was performed on 14 cases of each of the gut microbiota metabolites of the study subjects using UPLC-MS/MS technology. Correlations between the characteristics of the gut microbiota and its metabolites, basic human parameters, glycolipid metabolism indicators, and inflammatory factors were analyzed using spearman analysis.
UNASSIGNED: Glycolipid metabolism indexes and inflammatory factors were higher in normal-weight T2DM patients than in the healthy population (P<0.05), but body weight, BMI, waist circumference, and inflammatory factor concentrations were lower in normal-weight T2DM patients than in obese T2DM patients (P<0.05). Treatment with metformin in T2DM patients improved glycolipid metabolism, but the recovery of glycolipid metabolism was more pronounced in obese T2DM patients. None of the differences in α-diversity indexes were statistically significant (P>0.05), and the differences in β-diversity were statistically significant (P <0.05). Community diversity and species richness recovered after metformin intervention compared to before, and were closer to the healthy population. We found that Anaerostipes/Xylose/Ribulose/Xylulose may play an important role in the treatment of normal-weight T2DM with metformin by improving glycemic lipids and reducing inflammation. And Metformin may play a role in obese T2DM through Romboutsia, medium-chain fatty acids (octanoic acid, decanoic acid, and dodecanoic acid).
UNASSIGNED: Gut microbial dysbiosis and metabolic disorders were closely related to glucose-lipid metabolism and systemic inflammatory response in normal-weight T2DM patients. Metformin treatment improved glucose metabolism levels, systemic inflammation levels in T2DM patients, closer to the state of healthy population. This effect may be mediated by influencing the gut microbiota and microbial host co-metabolites, mainly associated with Anaerostipes and xylose/Ribulose/Xylulose. Metformin may exert its effects through different pathways in normal-weight versus obese T2DM patients.